Mumbai-based Glenmark Pharmaceuticals have launched a new antiviral drug - Favipiravir with brand name FabiFlu - for the treatment of mild to moderate Covid-19 patients. The firm has become the first Indian company to commercially launch the antiviral drug. Indian drug regulator Drug Controller General of India (DCGI) gave the company approval for marketing and manufacturing after which the product was launched in the Indian market today.
A pack of 34 tablets of FabiFlu has been priced at Rs 3,500 (Rs 103 per tablet). The dosage is 200 mg X 9 tablets on day one and 200 mg X 4 tablets a day for 14 days of the treatment. However, it should only be taken after a doctor's prescription. A clinical trial was conducted by Glenmark among 90 mild and 60 moderate Covid-19 patients across 11 sites in India. The drug is claimed to have an efficacy of over 80% in the treatment of mild to moderate Covid-19 patients.
It appears Glenmark will see a huge upsurge on the opening of the market in view of this news as it came after closing of the market on last Friday. Buy at the opening to get good appreciation during the day.
Wanna make money in the stock market, then trading with best intraday trading tips provider will be a better option or for all those looking for a fast buck can consider going in for the Bank Nifty option tips which gets you quick profit.